北京德恒律师事务所 北京德恒律师事务所 关于东北制药集团股份有限公司 2025 年第一次临时股东大会的法律意见 关于东北制药集团股份有限公司 2025 年第一次临时股东大会的 法律意见 北京市西城区金融街 19 号富凯大厦 B 座 12 层 电话：010-52682888 传真：010-52682999 邮编：100033 北京德恒律师事务所 关于东北制药集团股份有限公司 2025 年第一次临时股东大会的 法律意见 德恒 01G20240159 号 致：东北制药集团股份有限公司 东北制药集团股份有限公司（以下简称"公司"）2025 年第一次临时股东 大会（以下简称"本次会议"）于 2025 年 6 月 20 日（星期五）召开。北京德恒 律师事务所接受公司委托，指派李哲律师、王冰律师（以下简称"德恒律师"） 出席本次会议。根据《中华人民共和国公司法》(以下简称"《公司法》")、《中 华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》 （以下简称"《股东会规则》"）、《东北制药集团股份有限公司章程》（以下 简称"《公司章程》"）的规定，德恒律师就本次会议的召集、召开程序、现场 出席会议人员资格 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-050 东北制药集团股份有限公司 2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决议案的情形； 2．本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1.本次会议召开的时间： 出席会议的股东及股东授权委托代表共 208 名，代表股份 829,694,397 股， 占公司有表决权股份总数 58.1390％； 其中：出席现场会议的股东及股东授权委托代表共 3 名，代表股份 （1）现场会议召开时间：2025 年 6 月 20 日 14:00 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的具体时间为 2025 年 6 月 20 日 9:15 至 9:25，9:30 至 11:30，13:00 至 15:00；通过深圳证券 交易所互联网投票系统进行网络投票的具体时间为 2025 年 6 月 20 日 9:15 至 15:00。 2.现场会议地点：沈阳经济技术开发区昆明湖街 8 ...

Core Insights - Chinese companies are demonstrating strong capabilities in the stringent regulatory environment of the U.S. market, as evidenced by Northeast Pharmaceutical's successful completion of a three-day FDA inspection with "zero defects" [1][2][3] Group 1: FDA Inspection Details - The FDA's flying inspection is known for its surprise nature and strictness, assessing various aspects of the company's operations with minimal notice [2] - The inspection covered a wide range of products, including ten core items such as Vitamin C and L-Carnitine, and involved multiple departments within Northeast Pharmaceutical [2][3] Group 2: Quality Management System - Northeast Pharmaceutical's success is attributed to its long-standing commitment to quality management, having implemented food safety management systems since the 1990s and achieving various international certifications [3] - The flying inspection serves as a "pop quiz" for the company's daily quality management, reflecting the true level of its quality system [3] Group 3: Market Implications - The FDA certification acts as a significant "passport" and "credit endorsement" in international markets, enhancing the company's image and competitiveness [4] - With the successful FDA inspection, Northeast Pharmaceutical is expected to strengthen its relationships with international clients, driving overseas sales growth, projected to reach 902 million yuan in 2024, a 26.3% increase year-on-year [4]

证券代码：000597 证券简称：东北制药 公告编号：2025-049 东北制药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）2024 年年度权益分派方案 已获公司 2025 年 4 月 24 日召开的 2024 年度股东大会审议通过，现将权益分派 事宜公告如下： 一、股东大会审议通过利润分派方案情况 司 2024 年度利润分配预案的议案》，同意公司 2024 年度利润分配方案为：以公 司总股本 1,429,103,265 股为基数，向全体股东按每 10 股派发现金红利 1 元（含 税），共计分配现金红利 142,910,326.50 元，不送红股，不以公积金转增股本。 如在实施权益分派的股权登记日前公司总股本及应分配股数发生变动，拟维持每 股分配比例不变，相应调整分配总额。 注销 2022 年限制性股票激励计划部分限制性股票 2,015,000 股，公司总股本由 公司回购注销的股票激励计划部分限制性股票 2,015,000 股后的 1,427,088,265 股为基数，按照分配比例不变的原则对 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-049 东北制药集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 东北制药集团股份有限公司（以下简称"公司"）2024 年年度权益分派方案 已获公司 2025 年 4 月 24 日召开的 2024 年度股东大会审议通过，现将权益分派 事宜公告如下： 一、股东大会审议通过利润分派方案情况 1.公司于 2025 年 4 月 24 日召开的 2024 年度股东大会审议通过了《关于公 司 2024 年度利润分配预案的议案》，同意公司 2024 年度利润分配方案为：以公 司总股本 1,429,103,265 股为基数，向全体股东按每 10 股派发现金红利 1 元（含 税），共计分配现金红利 142,910,326.50 元，不送红股，不以公积金转增股本。 如在实施权益分派的股权登记日前公司总股本及应分配股数发生变动，拟维持每 股分配比例不变，相应调整分配总额。 2.自上述利润分派方案披露至实施期间，公司于 2025 年 6 月 13 日完成回购 注销 202 ...

Core Viewpoint - The recent shareholding increase by Jiangxi Fangda Steel Group, a concerted action party of the controlling shareholder Fangda Group, in Northeast Pharmaceutical Group signifies a strong confidence in the company's intrinsic value and future prospects, marking a new chapter of high-quality development for the company [1][2][9] Group 1: Shareholding Increase - Fangda Steel has completed its shareholding increase plan, raising its stake in Northeast Pharmaceutical to nearly 56%, indicating a significant commitment beyond mere financial investment [1][2] - This action reflects a belief that the current market valuation does not accurately represent the company's true value and future potential, presenting an attractive opportunity for further investment [2][9] Group 2: Protection of Minority Investors - The controlling shareholder's investment serves as a protective measure for minority investors, reinforcing market expectations and demonstrating a commitment to long-term development [3][9] - The increase in shareholding does not alter the company's control structure, aiming to enhance investor confidence and promote sustainable growth [3] Group 3: Internal Growth Drivers - Northeast Pharmaceutical is focusing on "R&D innovation" and "international expansion" as dual engines for growth, transitioning from traditional to modern development models [4][5] - The recent achievement of obtaining the European Pharmacopoeia Certificate (CEP) for its active pharmaceutical ingredient signifies a major milestone, allowing the company to access high-value European markets [4] Group 4: Strategic Investments - The company has significantly increased its investment in R&D in the first quarter of 2025, reflecting a long-term vision amidst a cost-cutting trend in the pharmaceutical industry [5] - This strategic focus on R&D is expected to yield new products and establish competitive advantages, supporting the company's long-term value growth [5] Group 5: External Expansion - Northeast Pharmaceutical is also pursuing external growth through strategic acquisitions, such as the recent purchase of Beijing Dingcheng Peptide Source Biopharmaceutical Company, which enhances its product offerings and market reach [6][8] - The acquisition aims to create synergies in product lines and R&D capabilities, thereby increasing overall market penetration and brand influence [7][8] Group 6: Future Outlook - The combination of internal growth, strategic acquisitions, and strong support from the controlling shareholder positions Northeast Pharmaceutical for a significant value return and operational success [9] - The current developments suggest a pivotal moment for the company, indicating a successful transformation and potential for renewed market recognition [9]

股。 分公司完成回购注销手续。 公司于 2023 年 11 月 13 日召开第九届董事会第二十二次会议、第九届监事会 第十八次会议、2023 年 11 月 29 日召开 2023 年第四次临时股东大会审议通过了 《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限 制性股票的议案》；于 2024 年 7 月 25 日召开第九届董事会第二十八次会议、第 九届监事会第二十二次会议、2024 年 9 月 12 日召开 2024 年第二次临时股东大会 审议通过了《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除 限售的限制性股票的议案》，现将有关事项说明如下： 一、公司 2022 年限制性股票激励计划已履行的相关审批程序 于公司〈2022 年限制性股票激励计划（草案）〉及其摘要的议案》 证券代码：000597 证券简称：东北制药 公告编号：2025-048 东北制药集团股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 股票激励计划所涉及的 26 名不符合条件的激励对象持有的部分或全部已获授但 尚未解除限 ...

证券代码：000597 证券简称：东北制药 公告编号：2025-048 东北制药集团股份有限公司 1.东北制药集团股份有限公司（以下简称"公司"）已完成对 2022 年限制性 股票激励计划所涉及的 26 名不符合条件的激励对象持有的部分或全部已获授但 尚未解除限售的 2,015,000 股限制性股票进行回购注销，占回购注销前公司总股 本的 0.1410%。 2.回购注销完成后，公司总股本将由 1,429,103,265 股减少至 1,427,088,265 股。 3.截至本公告日，上述限制性股票已在中国证券登记结算有限责任公司深圳 分公司完成回购注销手续。 公司于 2023 年 11 月 13 日召开第九届董事会第二十二次会议、第九届监事会 第十八次会议、2023 年 11 月 29 日召开 2023 年第四次临时股东大会审议通过了 《关于拟回购注销 2022 年限制性股票激励计划部分已获授但尚未解除限售的限 制性股票的议案》；于 2024 年 7 月 25 日召开第九届董事会第二十八次会议、第 九届监事会第二十二次会议、2024 年 9 月 12 日召开 2024 年第二次临时股东大会 审议通过了《关于拟回 ...

Core Insights - Northeast Pharmaceutical has officially obtained the CEP certificate for its core raw material product, fosfomycin trometamol, from the European Directorate for the Quality of Medicines (EDQM), marking a significant milestone as the first domestic pharmaceutical company to achieve this certification [1][2] - The CEP certificate serves as a "golden key" for entering the European and American markets, indicating that the product meets stringent quality standards that exceed typical international registration requirements [2] - The certification enhances Northeast Pharmaceutical's international brand value and strengthens China's position in the global antibiotic sector [2][3] Market Potential - Fosfomycin trometamol is recognized for its low resistance characteristics and is suitable for treating various infections, making it highly relevant in the context of the global antibiotic resistance crisis [3] - The demand for high-quality antibiotic raw materials in the European market is on the rise, and the CEP certification is expected to boost the market penetration of Northeast Pharmaceutical's products in Europe [3] Competitive Position - Northeast Pharmaceutical has established a robust international registration matrix, with approximately 20 raw material products having passed high-end registrations in various countries, including the EU, Japan, and Russia [4] - The company is a major supplier of vitamin C and holds significant positions in the global supply of fosfomycin and chloramphenicol, maintaining a competitive edge in the international market [4] - The company aims to leverage its CEP registration to enhance its global market share and transition from "product export" to "brand export," thereby gaining greater international respect for Chinese pharmaceuticals [5]

Group 1 - Libet has received approval from the China Securities Regulatory Commission for the issuance of convertible bonds, valid for 12 months [1] - Dinglong plans to acquire an additional 8% stake in its subsidiary, increasing its ownership from 91.35% to 99.35% for a total price of 240 million yuan [1] - Longyuan Donggu has been designated as a supplier for a major automotive project, with an expected total sales amount of 450 to 500 million yuan over five years [14] Group 2 - Luoniushan reported a sales revenue of 100 million yuan in May, a year-on-year decrease of 11.45% [2] - Baoming Technology has secured a loan commitment of up to 7 million yuan for stock repurchase [2] - Xinhua Pharmaceutical has received approval for the listing of a new chemical raw material used in treating chronic heart failure and hypertension [3] Group 3 - China Minmetals announced a new contract amount of 396 billion yuan for the first five months of the year, a decrease of 22.2% year-on-year [7] - Zhongbei Communication's application for a specific stock issuance has been accepted by the Shanghai Stock Exchange [8] - Rongfa Nuclear Power plans to issue bonds not exceeding 1 billion yuan to repay debts and supplement working capital [9] Group 4 - Phoenix Optical plans to invest 8.5 million USD to establish a wholly-owned subsidiary in Vietnam for manufacturing optical products [11] - Xiamen Airport reported a passenger throughput of 2.4752 million in May, a year-on-year increase of 8.34% [12] - Weilan Biological has received a new veterinary drug registration certificate for a product aimed at treating canine allergies and inflammation [13] Group 5 - Shouxiangu has completed the registration of a health food product that claims to enhance immunity [13] - Xingye Yinxin's subsidiary has passed a resource reserve verification report, confirming significant mineral reserves [16] - Shaanxi Construction has won two major projects with a total contract value exceeding 2.8 billion yuan [18] Group 6 - Huari received a cash dividend of 50 million yuan from its subsidiary [20] - Zhongchu's deputy general manager has resigned due to governance arrangements [21] - Kexin Pharmaceutical's core product has received breakthrough therapy designation from the National Medical Products Administration [39]